Aspira Women's Health Files 8-K
Ticker: AWHL · Form: 8-K · Filed: Dec 31, 2025 · CIK: 926617
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Aspira Women's Health filed an 8-K on Dec 29, 2025. Check for updates.
AI Summary
Aspira Women's Health Inc. filed an 8-K on December 29, 2025, reporting on events that occurred on the same date. The filing is a current report under Regulation FD and includes financial statements and exhibits. The company, previously known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and operates in the diagnostic substances sector.
Why It Matters
This 8-K filing indicates a routine update or disclosure from Aspira Women's Health Inc. to the SEC, potentially containing important information for investors.
Risk Assessment
Risk Level: low — This filing appears to be a standard 8-K disclosure without immediate indications of significant financial distress or major corporate events.
Key Numbers
- 001-34810 — SEC File Number (Identifies the company's filing with the SEC)
- 33-0595156 — EIN (Employer Identification Number for the company)
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- December 29, 2025 (date) — Date of earliest event reported
- Vermillion, Inc. (company) — Former company name
- Ciphergen Biosystems Inc (company) — Former company name
- Abiotic Systems (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates it is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, including Regulation FD Disclosure and Financial Statements and Exhibits, for the period ending December 29, 2025.
What is the primary business of Aspira Women's Health Inc.?
Aspira Women's Health Inc. operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' sector, as indicated by its SIC code [2835].
When did Aspira Women's Health Inc. change its name from Vermillion, Inc.?
The date of the name change from Vermillion, Inc. was August 24, 2007.
Where is Aspira Women's Health Inc. headquartered?
The company's business address is 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.
What is the fiscal year end for Aspira Women's Health Inc.?
The fiscal year end for Aspira Women's Health Inc. is December 31.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-12-31 07:00:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 AWHL OTC QX Market Indicate by ch
Filing Documents
- awhl-20251229x8k.htm (8-K) — 38KB
- awhl-20251229xex99d1.htm (EX-99.1) — 53KB
- awhl-20251229xex99d1g001.jpg (GRAPHIC) — 199KB
- awhl-20251229xex99d1g002.jpg (GRAPHIC) — 439KB
- awhl-20251229xex99d1g003.jpg (GRAPHIC) — 290KB
- awhl-20251229xex99d1g004.jpg (GRAPHIC) — 214KB
- awhl-20251229xex99d1g005.jpg (GRAPHIC) — 259KB
- awhl-20251229xex99d1g006.jpg (GRAPHIC) — 252KB
- awhl-20251229xex99d1g007.jpg (GRAPHIC) — 229KB
- awhl-20251229xex99d1g008.jpg (GRAPHIC) — 202KB
- awhl-20251229xex99d1g009.jpg (GRAPHIC) — 213KB
- awhl-20251229xex99d1g010.jpg (GRAPHIC) — 166KB
- awhl-20251229xex99d1g011.jpg (GRAPHIC) — 184KB
- awhl-20251229xex99d1g012.jpg (GRAPHIC) — 124KB
- awhl-20251229xex99d1g013.jpg (GRAPHIC) — 248KB
- awhl-20251229xex99d1g014.jpg (GRAPHIC) — 166KB
- awhl-20251229xex99d1g015.jpg (GRAPHIC) — 305KB
- awhl-20251229xex99d1g016.jpg (GRAPHIC) — 235KB
- awhl-20251229xex99d1g017.jpg (GRAPHIC) — 158KB
- awhl-20251229xex99d1g018.jpg (GRAPHIC) — 289KB
- awhl-20251229xex99d1g019.jpg (GRAPHIC) — 164KB
- awhl-20251229xex99d1g020.jpg (GRAPHIC) — 222KB
- awhl-20251229xex99d1g021.jpg (GRAPHIC) — 179KB
- awhl-20251229xex99d1g022.jpg (GRAPHIC) — 295KB
- awhl-20251229xex99d1g023.jpg (GRAPHIC) — 197KB
- awhl-20251229xex99d1g024.jpg (GRAPHIC) — 158KB
- awhl-20251229xex99d1g025.jpg (GRAPHIC) — 121KB
- awhl-20251229xex99d1g026.jpg (GRAPHIC) — 250KB
- awhl-20251229xex99d1g027.jpg (GRAPHIC) — 181KB
- awhl-20251229xex99d1g028.jpg (GRAPHIC) — 180KB
- awhl-20251229xex99d1g029.jpg (GRAPHIC) — 171KB
- awhl-20251229xex99d1g030.jpg (GRAPHIC) — 255KB
- awhl-20251229xex99d1g031.jpg (GRAPHIC) — 155KB
- awhl-20251229xex99d1g032.jpg (GRAPHIC) — 169KB
- awhl-20251229xex99d1g033.jpg (GRAPHIC) — 182KB
- awhl-20251229xex99d1g034.jpg (GRAPHIC) — 243KB
- awhl-20251229xex99d1g035.jpg (GRAPHIC) — 87KB
- 0000926617-25-000014.txt ( ) — 10362KB
- awhl-20251229.xsd (EX-101.SCH) — 3KB
- awhl-20251229_lab.xml (EX-101.LAB) — 16KB
- awhl-20251229_pre.xml (EX-101.PRE) — 10KB
- awhl-20251229x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 29, 2025, Aspira Women's Health Inc. (the "Company") published an investor presentation on its website. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report filing on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Slide Deck Published by Aspira Women's Health On December 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: December 31, 2025 ASPIRA WOMEN'S HEALTH INC. By: /s/ Michael Buhle Name: Michael Buhle Title: Chief Executive Officer